A new approach to identifying “signposts” on cancer cells may help immune cells eliminate the disease
With new immunotherapy treatments for melanoma, recovery rates have risen dramatically, in some cases to around 50%. But they could be much higher: A new study led by researchers at the Weizmann Institute of Science showed, in lab dishes and animal studies, that a highly personalized approach could help the immune cells improve their abilities to recognize the cancer and kill it. The results of this study were published today in Cancer Discovery.
Today’s immunotherapies involve administering antibodies to unlock the natural immune T cells that recognize and kill cancer cells; or else growing and reactivating these T cells outside the body and returning them in a ‘weaponized’ form. “But none of this will kill the cancer if the immune cells do not recognize the ‘signposts’ that mark cancer cells as foreign,” says Prof. Yardena Samuels of the Institute’s Molecular Cell Biology Department.
Groups around the world are searching for such signposts – mutated peptides known as neo-antigens on the cancer cells’ outer membranes. Identifying the particular peptides that present themselves to the T cell can then help develop personalized cancer vaccines based on neo-antigen profiles. One of the problems in uncovering neo-antigens in cancers like melanoma, however, is that they are presented by a protein complex called HLA – a complex that can come in thousands of versions, even without the addition of cancerous mutations. Indeed, the algorithms that are often used to search the cancer-cell genome for possible neo-antigens had predicted hundreds of possible candidates.
Fewer neo-antigens, better results
Samuels, together with her PhD student Shelly Kalaora and in collaboration with Prof Arie Admon of the Technion – Israel Institute of Technology, bypassed the algorithm methods. They used a method Admon had developed to remove the peptides from the melanoma cells’ HLA complex and investigate their interactions with T cells. Says Samuels: “We discovered that tumors present many fewer neo-antigens than we expected. Our neo-antigen and corresponding T-cell-identification strategies were so robust, our neo-antigen-specific T cells killed 90% of their target melanoma cells both on plates and in mice. This suggests possible clinical applications for the near future. Some of the peptides we identified are neo-antigens that had not even shown up in the algorithm studies; in other words, the method we used, called HLA peptidomics, is really complementary to these methods.
Samuels and Kalaora worked with a team that included Dr. Eytan Ruppin of the National Cancer Institute, USA; Dr. Jennifer Wargo of the University of Texas MD Anderson Cancer Center, Houston, and Prof. Nir Friedman of the Weizmann Institute of Science’s Molecular Cell Biology Department.
Neo-antigen-specific T cells killed 90% of their target melanoma cells
For some of the patients the group had obtained multiple samples, and this enabled them to ask questions about metastasis – for example, whether the same neo-antigens were present on secondary tumors after the cancer had spread to other organs. “This is the first time that HLA peptide studies of multiple metastases derived from the same patient have ever been performed. The significant similarity between the various HLA-peptidomes has strong implications for the process of choosing neo-antigens for patient treatment, showing that it is clearly essential not only to identify the immunogenic peptides presented on the cancer cells, but to select the ones that are common to the patient’s metastases. This can then help direct systemic therapeutic responses in patients with multiple metastases,” says Kalaora.
A new drug for every patient
And then the group took their findings one step further: Using natural T cells extracted from 14 of the patients, the researchers identified those that most strongly react with the neo-antigens. They sequenced the genomes of these cells, grew them and tested them in animal models with the patients’ tumor cells. In both lab dish experiments and mice, they showed that the response of the T cells they identified was highly effective in fighting the cancer.
Samuels points out that “although this research is experimental right now, the findings are highly relevant to clinical research, as groups around the world have already worked out the basics of developing therapeutic anti-cancer treatments based on neo-antigens. As almost all the neo-antigens detected in patients thus far are individual – and unique to the particular cancerous tissue – they constitute an ideal class of anti-cancer targets. This would be the ultimate “personalized” cancer therapy – a new drug is created for every patient.”
The Latest on: Neo-antigens
[google_news title=”” keyword=”neo-antigens” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Neo-antigens
- Identification and Characterization of Neoantigens for Cancer Immunotherapyon December 3, 2023 at 11:58 pm
At the core of each immunotherapy are neoantigens that drive effective T cell response, i.e. peptides that arise from the expression of somatically mutated genes. Hence, the characterization of ...
- Non-Canonical Neoantigens in Canceron November 30, 2023 at 4:00 pm
Neoantigens are tumor-specific antigens derived from somatic genomic aberrations and are drivers of anti-cancer immunity by their presentation to T cells via MHC. Several neoantigen targeting ...
- HLA Binding Affinity-based Screening of Neoantigenson November 26, 2023 at 4:01 pm
« Full Moon Snowshoe Tour Tahoe Flow Arts & Fitness Basic & Performance Aerial Arts Classes Start November 27 for Our Holiday Bazaar! » Moonshine Ink is independently owned and operated, meaning we ...
- 5 Cancer Vaccines to Watch in 2024on November 19, 2023 at 4:00 pm
Progress in personalized medicine has made it easier and much more affordable to sequence patient genomes, pull out unique cancer signatures and make vaccines encoding these neoantigens. BioSpace ...
- Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texason November 16, 2023 at 7:13 am
The company’s pioneering immuno-oncology therapy, Vigil, decloaks the full repertoire of tumor antigens, including the patient’s clonal neoantigens, reactivates the immune system, and summons ...
- Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlightson November 13, 2023 at 2:26 pm
“We are pleased with progress across the scientific field that continues to demonstrate the importance of neoantigens as the most attractive targets in solid-tumor oncology. We believe that our ...
- Alternative Splicing in Tumors — A Path to Immunogenicity?on November 1, 2023 at 5:00 pm
2 It has been recognized for some time that aberrant splicing may produce neoantigens. The performance of systematic analyses has been challenging for many reasons, including the lack of good ...
- NEC: harnessing artificial intelligence-powered drug development to provide tailored medicineson April 11, 2022 at 9:28 am
A promising alternative to targeting TAAs is to develop vaccines against cancer neoantigens. These are de novo altered self-peptides created by specific mutations in a patient’s tumor ...
via Bing News